Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
26/06/2026 15:11
BUZZ-Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal ** Shares of drugmaker Biogen BIIB.O rise 5.8% to $213.75 premarket
** Biogen says it has either paused or discontinued funding for most of the research programs included in its $5.6 billion acquisition of Apellis Pharmaceuticals' assets
** The U.S. drugmaker has also cut a small number of roles within the research organization as it shifts resources toward Empaveli and Syfovre, the approved therapies acquired through the deal
** The company did not offer details on the number of roles or the specific programs impacted by the decision
** Including session's move, BIIB shares up 20% YTD
(Reporting by Padmanabhan Ananthan)
Recent news on Biogen
See all newsHealth Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout